| Jefferson Mark Prichard, MD | |
|
500 Martha Jefferson Dr, Charlottesville, VA 22911 | |
| (434) 654-8390 | |
| (434) 654-8399 |
| Full Name | Jefferson Mark Prichard |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 24 Years |
| Location | 500 Martha Jefferson Dr, Charlottesville, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609899400 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 0101232678 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Rmh Medical Center | Harrisonburg, VA | Hospital |
| Sentara Martha Jefferson Hospital | Charlottesville, VA | Hospital |
| University Of Virginia Medical Center | Charlottesville, VA | Hospital |
| Page Memorial Hospital, Inc | Luray, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Martha Jefferson Medical Group Llc | 5991889081 | 181 |
| Rmh Medical Group Llc | 7618270729 | 208 |
| Ivyrehab Sept, Llc | 7911990908 | 1137 |
News Archive
Isotechnika Pharma Inc. announces that the results of the CONFIRM1 clinical trial conducted by its medical device partner, Atrium Medical Corporation, were presented by Glenn Van Langenhove, MD, PhD (Middelheim Hospital in Antwerp, Belgium), the principal investigator, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Scientific Symposium in Washington, DC last week.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
The Seattle Times examines how the Bill & Melinda Gates Foundation's goal to eradicate malaria is shaping aspects of global research.
Researchers in China may have found a method for male contraception that is effective, reversible and without serious short-term adverse effects according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
› Verified 9 days ago
| Entity Name | Martha Jefferson Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275720559 PECOS PAC ID: 5991889081 Enrollment ID: O20080228000055 |
News Archive
Isotechnika Pharma Inc. announces that the results of the CONFIRM1 clinical trial conducted by its medical device partner, Atrium Medical Corporation, were presented by Glenn Van Langenhove, MD, PhD (Middelheim Hospital in Antwerp, Belgium), the principal investigator, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Scientific Symposium in Washington, DC last week.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
The Seattle Times examines how the Bill & Melinda Gates Foundation's goal to eradicate malaria is shaping aspects of global research.
Researchers in China may have found a method for male contraception that is effective, reversible and without serious short-term adverse effects according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
› Verified 9 days ago
| Entity Name | Rmh Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669844908 PECOS PAC ID: 7618270729 Enrollment ID: O20160125000666 |
News Archive
Isotechnika Pharma Inc. announces that the results of the CONFIRM1 clinical trial conducted by its medical device partner, Atrium Medical Corporation, were presented by Glenn Van Langenhove, MD, PhD (Middelheim Hospital in Antwerp, Belgium), the principal investigator, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Scientific Symposium in Washington, DC last week.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
The Seattle Times examines how the Bill & Melinda Gates Foundation's goal to eradicate malaria is shaping aspects of global research.
Researchers in China may have found a method for male contraception that is effective, reversible and without serious short-term adverse effects according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jefferson Mark Prichard, MD 500 Martha Jefferson Dr, Charlottesville, VA 22911-4668 Ph: (434) 654-8390 | Jefferson Mark Prichard, MD 500 Martha Jefferson Dr, Charlottesville, VA 22911 Ph: (434) 654-8390 |
News Archive
Isotechnika Pharma Inc. announces that the results of the CONFIRM1 clinical trial conducted by its medical device partner, Atrium Medical Corporation, were presented by Glenn Van Langenhove, MD, PhD (Middelheim Hospital in Antwerp, Belgium), the principal investigator, at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 Scientific Symposium in Washington, DC last week.
BioTime, Inc., a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the third quarter and nine months ended September 30, 2011 and highlighted recent corporate accomplishments.
The Seattle Times examines how the Bill & Melinda Gates Foundation's goal to eradicate malaria is shaping aspects of global research.
Researchers in China may have found a method for male contraception that is effective, reversible and without serious short-term adverse effects according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).
› Verified 9 days ago
Daniel S. Strand, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1240 Lee St, Charlottesville, VA 22908 Phone: 434-243-5233 Fax: 434-244-7526 | |
Dr. Numaan F. Malik, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Lee St Fl 2, Charlottesville, VA 22908 Phone: 434-924-5219 Fax: 434-924-9720 | |
Dr. Asma Shahid Habib, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1204 W Main St, Charlottesville, VA 22903 Phone: 434-924-9119 Fax: 434-924-3300 | |
Amber N. Inofuentes, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-243-4288 Fax: 434-243-7310 | |
Mark Thomas Worthington, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1215 Lee St, Charlottesville, VA 22908 Phone: 434-243-3090 Fax: 434-244-9445 | |
Dr. Emanuel Cirenza, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 590 Peter Jefferson Place, Suite 175, Charlottesville, VA 22911 Phone: 434-982-6900 Fax: 434-982-8420 | |
Warren K. Bolton, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: Uva Hospital W, Hospital Drive, Charlottesville, VA 22908 Phone: 434-924-1984 Fax: 434-924-5898 |